Skip to main content

Table 1 Baseline characteristics of patients by infection group

From: Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon

 

HIV monoinfected patients (n = 134)

HBV or HCV coinfected patients (n = 35)

p

Women (no.)

91

(68%)

22

(63%)

0.6

Age (years)

     

   Median (IQR)

34.5

(28.4-39.7)

41.6

(33.7-48.8)

<0.001

   <42 (no.)

113

(84%)

19

(54%)

<0.001

Time since diagnosis of HIV seropositivity (months)

     

   Median (IQR)

29.4

(13.5-53.4)

22.1

(8.3-43.6)

0.2

   <24 (no.)

56

(42%)

18

(51%)

0.3

Body weight (Kg) [median (IQR)]

65

(55-70)

63

(54-70)

0.7

Body mass index (Kg/m2)*

     

   median (IQR)

23.2

(21.6-24.7)

22.2

(20.6-25.6)

0.2

   ≥ 21 (no.)

108

(82%)

25

(74%)

0.3

Karnofsky score >90% (no.)

72

(54%)

15

(43%)

0.3

CDC clinical stage (no.)

    

0.7

   A

19

(14%)

4

(11%)

 

   B

58

(43%)

13

(37%)

 

   C

57

(43%)

18

(51%)

 

CD4 cell count (/mm3)

     

   Median (IQR)

138

(67-222)

135

(68-216)

0.7

   <100 (no.)

80

(60%)

22

(63%)

0.7

HIV-1 viral load (log10 copies/mL)

     

   Median (IQR)

5.3

(4.7-5.5)

5.3

(4.8-5.7)

0.5

   <5.0 (no.)

50

(37%)

11

(31%)

0.5

Hemoglobin (g/dL)

     

   Median (IQR)

11.0

(9.8-12.1)

11.1

(9.8-12.9)

0.6

   <10 (no.)

36

(27%)

10

(29%)

0.8

Total lymphocyte count (/mm3)

     

   Median (IQR)

1578

(1080-2100)

1408

(1000-1900)

0.4

   <1700 (no.)

77

(57%)

23

(66%)

0.4

ALT level (×ULN)

     

   Median (IQR)

0.6

(0.4-0.7)

0.8

(0.6-1.2)

<0.001

   ≥ 1.25 (no.)

8

(6%)

8

(30%)

0.002

ASAT (×ULN)

     

   Median (IQR)

0.8

(0.6-1.1)

1.3

(0.9-1.7)

<0.001

   ≥ 1.25 (no.)

21

(17%)

17

(52%)

<0.001

History of antiretroviral treatment (no.)

    

0.6

   None

131

(98%)

34

(97%)

 

   HAART

1

(1%)

1

(3%)

 

   Nevirapine (PMTCT)

2

(2%)

0

-

 

Baseline antiretroviral treatment (no.)

    

0.3

   Zidovudine+lamivudine+nevirapine

70

(52%)

15

(43%)

 

   Stavudine+lamivudine+nevirapine

64

(48%)

20

(57%)

 

Cotrimoxazole prophylaxis (no.)

124

(93%)

35

(100%)

0.1

  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; PMTCT, prevention of mother-to-child transmission; HAART, highly active antiretroviral therapy
  2. * 3 missing values; 1 missing value; 9 missing values